Award

Meningitis B Vaccine (2026)

SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE ACTING AS PART OF THE CROWN THROUGH UK HEALTH SECURITY AGENCY

This public procurement record has 2 releases in its history.

Award

22 May 2026 at 14:42

Award

09 Sep 2025 at 10:08

Summary of the contracting process

The procurement process for the Meningitis B Vaccine (2026) was conducted by the Secretary of State for Health and Social Care, acting through the UK Health Security Agency, located in London, United Kingdom. This procurement falls under the industry category of vaccines and is part of a national childhood immunisation programme, also aimed at protecting at-risk adults against Gonorrhoea. The process has reached the award stage with a direct procurement method being utilised, which resulted in a contract award to GLAXOSMITHKLINE UK LIMITED. The contract period starts on 1st October 2026 and ends on 30th September 2029, with the possibility to extend through to 30th September 2030.

This tender process presents significant opportunities for businesses specialising in pharmaceuticals and vaccine production, especially those capable of fulfilling large-scale contracts for public health initiatives. The direct award method highlights the importance of possessing exclusive rights or specialised capabilities in vaccine development, positioning businesses with such advantages well for competition. Companies with expertise in pharmaceuticals and a strong presence in the immunisation sector, particularly those like GLAXOSMITHKLINE UK LIMITED, are well-suited to benefit from and contribute to the project's success.

Find more tenders on our Open Data Platform.
How relevant is this notice?

Notice Title

Meningitis B Vaccine (2026)

Notice Description

The provision of a vaccine to protect against meningococcal B (MenB) disease, to be used in the national childhood immunisation programme, as well as a targeted programme to protect at risk adults against Gonorrhoea. Value - The contract value is withheld from publication pursuant to regulation 94(2)(b) of the Procurement Act 2023, so as not to prejudice the legitimate commercial interest of the supplier.

Procurement Information

The following conditions are met in relation to the public contract under Schedule 5, Paragraph 5 (a, b) of the Procurement Act 2023- (a) due to a particular supplier having intellectual property rights or other exclusive rights, only that supplier can supply the goods, services or works required, and (b)there are no reasonable alternatives to those goods, services or works.

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-059678
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/048141-2026
Current Stage
Award
All Stages
Award

Procurement Classification

Notice Type
UK6 - Contract Award Notice
Procurement Type
Standard
Procurement Category
Goods
Procurement Method
Direct
Procurement Method Details
Direct award
Tender Suitability
Not specified
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products


CPV Codes

33651600 - Vaccines

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
£1
Contracts Value
Not specified

Notice Dates

Publication Date
22 May 20261 weeks ago
Submission Deadline
Not specified
Future Notice Date
Not specified
Award Date
9 Sep 20258 months ago
Contract Period
30 Sep 2026 - 30 Sep 2029 3-4 years
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Complete
Awards Status
Pending
Contracts Status
Not Specified

Contracting Authority (Buyer)

Main Buyer
SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE ACTING AS PART OF THE CROWN THROUGH UK HEALTH SECURITY AGENCY
Additional Buyers

UK HEALTH SECURITY AGENCY

Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LONDON
Postcode
E14 4PU
Post Town
East London
Country
England

Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI4 Inner London - East
Small Region (ITL 3)
TLI42 Tower Hamlets
Delivery Location
Not specified

Local Authority
Tower Hamlets
Electoral Ward
Canary Wharf
Westminster Constituency
Poplar and Limehouse

Supplier Information

Number of Suppliers
1
Supplier Name

GLAXOSMITHKLINE

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

Download

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-059678-2026-05-22T15:42:34+01:00",
    "date": "2026-05-22T15:42:34+01:00",
    "ocid": "ocds-h6vhtk-059678",
    "initiationType": "tender",
    "parties": [
        {
            "id": "GB-NHS-U6N4T",
            "name": "UK Health Security Agency",
            "identifier": {
                "scheme": "GB-NHS",
                "id": "U6N4T"
            },
            "additionalIdentifiers": [
                {
                    "scheme": "GB-PPON",
                    "id": "PBMQ-7576-DVGW"
                }
            ],
            "address": {
                "streetAddress": "10 South Colonnade",
                "locality": "London",
                "postalCode": "E14 4PU",
                "country": "GB",
                "countryName": "United Kingdom",
                "region": "UKI42"
            },
            "contactPoint": {
                "email": "vmc.vaccines@ukhsa.gov.uk"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.gov.uk/government/organisations/uk-health-security-agency",
                "classifications": [
                    {
                        "id": "publicAuthorityCentralGovernment",
                        "scheme": "UK_CA_TYPE",
                        "description": "Public authority - central government"
                    }
                ]
            }
        },
        {
            "id": "GB-PPON-PNVC-2547-YXMP",
            "name": "GLAXOSMITHKLINE UK LIMITED",
            "identifier": {
                "scheme": "GB-PPON",
                "id": "PNVC-2547-YXMP"
            },
            "address": {
                "streetAddress": "79 New Oxford Street",
                "locality": "London",
                "postalCode": "WC1A 1DG",
                "country": "GB",
                "countryName": "United Kingdom",
                "region": "UKI31"
            },
            "contactPoint": {
                "email": "customercontactuk@gsk.com"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large",
                "vcse": false,
                "url": "http://gsk.com",
                "publicServiceMissionOrganization": false,
                "shelteredWorkshop": false
            },
            "control": {
                "description": "Additional Entity 1: Name: Glaxo Group Limited Organisation Type: Parent or subsidiary company Control Condition: N/A"
            }
        },
        {
            "id": "GB-PPON-PBMQ-7576-DVGW",
            "name": "Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency",
            "identifier": {
                "scheme": "GB-PPON",
                "id": "PBMQ-7576-DVGW"
            },
            "address": {
                "streetAddress": "10 South Colonnade",
                "locality": "London",
                "postalCode": "E14 4PU",
                "country": "GB",
                "countryName": "United Kingdom",
                "region": "UKI42"
            },
            "contactPoint": {
                "email": "vmc.vaccines@ukhsa.gov.uk"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.gov.uk/government/organisations/uk-health-security-agency",
                "classifications": [
                    {
                        "id": "publicAuthorityCentralGovernment",
                        "scheme": "UK_CA_TYPE",
                        "description": "Public authority - central government"
                    }
                ]
            }
        }
    ],
    "buyer": {
        "id": "GB-PPON-PBMQ-7576-DVGW",
        "name": "Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency"
    },
    "tender": {
        "id": "C352798",
        "legalBasis": {
            "id": "2023/54",
            "scheme": "UKPGA",
            "uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents"
        },
        "title": "Meningitis B Vaccine (2026)",
        "description": "The provision of a vaccine to protect against meningococcal B (MenB) disease, to be used in the national childhood immunisation programme, as well as a targeted programme to protect at risk adults against Gonorrhoea. Value - The contract value is withheld from publication pursuant to regulation 94(2)(b) of the Procurement Act 2023, so as not to prejudice the legitimate commercial interest of the supplier.",
        "status": "complete",
        "procurementMethod": "direct",
        "procurementMethodDetails": "Direct award",
        "procurementMethodRationale": "The following conditions are met in relation to the public contract under Schedule 5, Paragraph 5 (a, b) of the Procurement Act 2023- (a) due to a particular supplier having intellectual property rights or other exclusive rights, only that supplier can supply the goods, services or works required, and (b)there are no reasonable alternatives to those goods, services or works.",
        "lots": [
            {
                "id": "1",
                "status": "complete"
            }
        ],
        "documents": [
            {
                "id": "conflictOfInterest",
                "documentType": "conflictOfInterest",
                "description": "Not published"
            }
        ],
        "riskDetails": "The below known unknown risks have been identified, which may require modification of the contract under paragraph 5 of Schedule 8 to the PA 2023 if one of the below identified risks materialise. Risk 1: The COVID-19 pandemic led to lockdown events, which disrupted the distribution and uptake of some national immunisation campaigns. The forecast delivery and stock requirements were substantially changed as a result. An ongoing risk is the materialisation of a UK health emergency or global pandemic, which may materialise in any given year. How the risk may impact on the performance of the contract: A health emergency or pandemic may materially affect the uptake of the MenB vaccine. Continued delivery of the vaccine within the original term of the contract could jeopardise stock management and effective use of vaccines before expiry. Why is it not possible to address the potential impact of such risks? UKHSA and suppliers cannot reasonably predict the occurrence of a pandemic. UKHSA cannot determine an effective delivery schedule and contract term which would be effective during a pandemic to mitigate the risk of reduced uptake. The possibility of contract modification if the risk materialises. If a pandemic event or health emergency occurs, then it is highly likely that the contract may need to be modified. Risk 2: A new meningococcal strain materialises, which changes the demand for the contracted meningococcal vaccine requiring additional volumes to be procured to provide protection to expanded cohorts. How the risk may impact on the performance of the contract. Should there be an increase in demand, then the current ordered volumes and planned delivery schedules would not provide for an expansion in the number of cohorts which need to be covered with MenB immunisations. Why is it not possible to address the potential impact of such risks? UKHSA considers available information from experts within UKHSA, JCVI and DHSC. However, UKHSA cannot anticipate the requirements of an unknown risk. The costs to provide contingency volumes for an unknown risk would be disproportionate to the likelihood of the risk materialising. The possibility of contract modification if the risk materialises: It would be likely that the contract would be amended if a new meningococcal strain materialises.",
        "procurementMethodRationaleClassifications": [
            {
                "id": "singleSuppliersIntellectualPropertyExclusiveRights"
            }
        ]
    },
    "awards": [
        {
            "id": "1",
            "title": "Meningitis B Vaccine (2026)",
            "status": "pending",
            "value": {
                "amountGross": 1,
                "amount": 1,
                "currency": "GBP"
            },
            "mainProcurementCategory": "goods",
            "aboveThreshold": true,
            "suppliers": [
                {
                    "id": "GB-PPON-PNVC-2547-YXMP",
                    "name": "GLAXOSMITHKLINE UK LIMITED"
                }
            ],
            "items": [
                {
                    "id": "1",
                    "additionalClassifications": [
                        {
                            "scheme": "CPV",
                            "id": "33651600",
                            "description": "Vaccines"
                        }
                    ],
                    "deliveryAddresses": [
                        {
                            "region": "UK",
                            "country": "GB",
                            "countryName": "United Kingdom"
                        },
                        {
                            "region": "UK",
                            "country": "GB",
                            "countryName": "United Kingdom"
                        }
                    ],
                    "relatedLot": "1"
                }
            ],
            "contractPeriod": {
                "startDate": "2026-10-01T00:00:00+01:00",
                "endDate": "2029-09-30T23:59:59+01:00",
                "maxExtentDate": "2030-09-30T23:59:59+01:00"
            },
            "hasRenewal": true,
            "renewal": {
                "description": "The contract may be extended provided that the aggregate extension period shall not exceed 12 months."
            },
            "relatedLots": [
                "1"
            ],
            "documents": [
                {
                    "id": "054928-2025",
                    "documentType": "awardNotice",
                    "noticeType": "UK5",
                    "description": "Transparency notice on Find a Tender",
                    "url": "https://www.find-tender.service.gov.uk/Notice/054928-2025",
                    "datePublished": "2025-09-09T11:08:31+01:00",
                    "format": "text/html"
                },
                {
                    "id": "048141-2026",
                    "documentType": "awardNotice",
                    "noticeType": "UK6",
                    "description": "Contract award notice on Find a Tender",
                    "url": "https://www.find-tender.service.gov.uk/Notice/048141-2026",
                    "datePublished": "2026-05-22T15:42:34+01:00",
                    "format": "text/html"
                }
            ],
            "milestones": [
                {
                    "id": "1",
                    "type": "futureSignatureDate",
                    "dueDate": "2026-06-05T23:59:59+01:00",
                    "status": "scheduled"
                }
            ],
            "date": "2026-05-22T00:00:00+01:00",
            "standstillPeriod": {
                "endDate": "2026-06-03T23:59:59+01:00"
            }
        }
    ],
    "language": "en"
}